23^rd International Conference on Nanomaterials science & Nanoengineering & Technology April 18-19, 2018
las Vegas | Nevada | USA

Biography:

P R Raghavan is a CEO of Nanorx Inc. and has a PhD in Organic Chemistry from Oregon State University (1979) and an MS in Chemistry (1972) from IIT, Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and international patents and another 15 pending patent applications.

Abstract:

Metadichol (US patent 8,722,093 and 9043,383) is a nano emulsion of long-chain alcohols found in many foods that is present in foods such as rice, sugar cane, wheat and peanuts. Metadichol acts as inverse/Protean agonist on Nuclear Vitamin D receptors (VDR) (US patents 9,006,292, 8,722.093, 9.034, 383) that are present in cells throughout the body to stimulate the immune system. Metadichol® is first of a class of unique nano emulsion molecules that are active against viruses, bacteria, and parasites. In addition to acting on VDR, it shows cross reactivity against other nuclear receptors and how this leads to mitigation of various chronic diseases like diabetes, hypertension etc. Gene expression analysis and human clinical case studies will be presented. Because, it consists of natural components of conventional foods and has no known negative side effects, Metadichol has the potential to serve as a novel, broad-spectrum treatment for many diseases that confront public health today bringing the concept of health care for all at a price we can afford.

Biography:

Thomas J Webster is the Chemical Engineering Art Zafiropoulo Chair at Northeastern University. His lab group published 9 textbooks, 48 book chapters, 403 articles, and 32 provisional/full patents. He has received numerous honors: 2012, Fellow, American Institute for Medical and Biological Engineering; 2013, Fellow, Biomedical Engineering Society; 2015, Wenzhou 580 Award; 2015, Zhejiang 1000 Talent Program; 2016, IMRC Chinese Academy of Science Lee-Hsun Lecture Award; 2016, Fellow, Biomaterials Science and Engineering; and 2016, Acta Biomaterialia Silver Award. He has regularly appeared on BBC, NBC, ABC, Fox, National Geographic, and many other news outlets. 144 students have graduated under him.

Abstract:

Objective: Nanotechnology (or the use of materials with one dimension less than 100nm) has been revolutionizing the field of medicine for several decades due to the ability of nanomaterials to mimic natural features of healthy tissues. However, issues remain such as toxicity, assembling nanomaterials into functional organs, efficacy, drug loading, cost and lengthy FDA approval times have still proven to be significant obstacles. The objective of this talk is to summarize recent advances in developing nanostructured artificial organs for quick regulatory approval.

 

Methods: Approaches such as top-down and bottom-up nano approaches along with 3D printing, cast-molding, and other techniques to create artificial organs will be covered. Approaches have been shown to be versatile using ceramics, metals, polymers and composites thereof. In vitro and in vivo studies will be covered. Nanoparticle synthesis will also be covered with challenges and promises.

 

Results: Such approaches have led to improved interactions with mammalian cells (such as bone, cartilage, vascular, neural, bladder, etc.,) and decreased interactions with immune cells (such as monocytes, macrophages, etc.,) to regenerate organs. Recently, results have shown the ability to decrease bacteria functions without using antibiotics. Lastly, a new approach to medicine focused on controlling Pico scale events will also be introduced where one can dictate electron interactions within a material to improve cellular functions leading to greater organ regeneration.

 

Conclusions: In summary, this talk will cover what has been learned over the past several decades of translating nanotechnology to improve organ replacement while emphasizing future developments that we should expect for the field to grow (such as Pico technology).

Biography:

Oara Neumann has completed her PhD and Post-doctoral study in Applied Physics at Rice University and MS from Weizmann Institute of Science, Israel, and Bucharest University, Romania. She is a Research Scientist in Naomi Halas group at Rice University. She holds 12 patents and has published more than 25 papers in reputed journals.

Abstract:

Multifunctional plasmonic nanostructures have enormous potential in the treatment of solid tumors; however, tracking particles with drug cargo and triggering the release of the cargo in mapped tumors is still impossible. To overcome this challenge, we have developed an MRI and fluorescent active nanostructure nanomatryoshka. This new nanostructure with IR plasmonic signatures is composed of a 50nm Au core surrounded by dye molecules and Gd(III)-DOTA chelate doped SiO₂ inner-shell and an outer Au shell. The experimental results demonstrate an enhanced T₁ relaxation (r₁ ~ 24mM^-1s^-1 at 4.7 T) compared to the clinical Gd(III)-DOTA chelating agents (r₁ ~ 4mM^-1s^-1). Further, this design preserves the fluorescence signal (65%) after 24 hours of exposure, leading to enhanced fluorescence photostability (23x). This dual-imaging functionality nanosystem increases MRI sensitivity by concentrating Gd(III) ions into the Gd-NMs, reduces the potential toxicity of Gd(III) ions and dye molecules by preventing their release in vivo through the outer Au shell protection, and the terminal gold layer surface can then be functionalized to increase cellular uptake, circulation time, or thermal drug-release properties.

Biography:

Yashwant Pathak has completed his PhD in Pharmaceutical Technology from Nagpur University, India and EMBA and MS in Conflict Management from Sullivan University. He is a Professor and Associate Dean for Faculty Affairs at College of Pharmacy, University of South Florida, Tampa, Florida. He has extensive experience in academia as well as industry, has more than 150 publications and two patents and two patent applications, 16 books including five books in Nanotechnology and five in Nutraceuticals and Drug Delivery Systems.

Abstract:

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in people 50 years of age or older in the developed world. More than eight million Americans have age-related macular degeneration, and the overall prevalence of advanced age-related macular degeneration is projected to increase by more than 50% by the year 2020. Recent advances in clinical research helps in better understanding of the genetics and pathophysiology of AMD. The systemic biology information which has revealed several mechanisms causing the AMD which can be used for developing new therapies designed to prevent and help treat it the AMD. With the advances in nanotechnology, characterization techniques of nanoparticles and the enormous surface nanoparticles provide if used as a carrier for drug, researches in the ophthalmic drug delivery are gearing towards using these NPDDS (Nano-particulate drug delivery systems) for treating AMD. We have used thermo reversible polymeric gel systems to deliver various drugs which hold promises to treat mitigate and prevent AMD. The review will cover various strategies based on systemic biology of AMD and our efforts to deliver the appropriate drugs to treat various symptoms of AMD using NPDDS.

Biography:

Jordi Arbiol has completed his graduation in Physics at Universitat de Barcelona (UB) in 1997, where he also obtained his PhD (European Doctorate and PhD Extraordinary Award) in 2001. He was an Assistant Professor at UB. From 2009 to 2015, he was the Group Leader at Institut de Ciència de Materials de Barcelona, ICMAB-CSIC. Since 2017, he has been the President of Spanish Microscopy Society (SME). Since 2015, he has become the leader of the Group of Advanced Electron Nanoscopy at Institut Català de Nanociència i Nanotecnologia (ICN2). He has been awarded with the EU40 Materials Prize 2014 (E-MRS) 2014 EMS Outstanding Paper Award and the PhD Extraordinary Award in 2001.

Abstract:

Technology at the nanoscale has become one of the main challenges in science as new physical effects appear and can be modulated at will. Superconductors, materials for spintronics, electronics, optoelectronics, sensing, energy applications and new generations of functionalized materials are taking advantage of the low dimensionality, improving their properties and opening a new range of applications. As developments in materials science are pushing to the size limits of physics and chemistry, there is a critical need for understanding the origin of these unique physical properties (optical and electronic) and relate them to the changes originated at the atomic scale, e.g., linked to changes in (electronic) structure of the material. In the present work, I will show how combining advanced electron microscopy imaging with electron spectroscopy, as well as cathodoluminescence in an aberration corrected STEM will allow us to probe the elemental composition and electronic structure simultaneously with the optical properties in unprecedented spatial detail. The talk will focus on several examples in advanced nanomaterials for optical, electronics and energy applications. In this way, the latest results obtained by my group on direct visualizing and modeling materials at atomic scale will help to understand their growth mechanisms (sometimes complex) and correlate their physical and chemical properties at sub-nanometer with their atomic scale structure. The examples will cover a wide range of nanomaterials: quantum structures self-assembled in a nanowire: quantum wires (1D) and quantum dots (0D) and other complex nanowire-like morphologies for photonic and energy applications (LEDs, lasers, quantum computing, single photon emitters, water splitting cells and batteries).

Biography:

Eleonora Babayants is the Founder and President of Galaxy Consulting. She is a Documentation Management Professional and hands-on consultant with over 25 years of experience in Documentation and Records Management, Document Control, Regulatory Compliance, Internal and External Auditing, Electronic Document Management Systems, Information Governance, and Change Management. Her past work includes Development and Implementation Regulatory Compliance Processes and Procedures, Leading Implementation and Administration of Document Control Systems in full Compliance with Regulatory Requirements, Enabling Enterprise Search, Improving Systems Information Architecture, Creating and Implementing Users Training Programs. She led Electronic Document Management Systems Selection and Deployment, administered and supported these systems, Web Information Portals, Knowledgebase Applications, Recommended and Implemented Re-Structuring of the content and the Information Architecture of these systems. She has worked very closely with IT to do feasibility assessment and to capture users’ requirements. Her experience spans multiple industries including Biomedical, Pharmaceutical, and Medical Devices Companies.

Abstract:

Documentation is a critical tool for ensuring GxP/GMP compliance. This is what GMP states about document control: each manufacturer shall establish and maintain procedures to control all documents that are required. In the regulated environment which must be GxP/GMP compliant, document control is the cornerstone of the quality system. It is so important that if an external audit identifies deficiencies in the document control system, the entire organization can be shut down. There are also GMP requirements for information technology. For a drug to be produced in a GxP/GMP compliant manner, some specific information technology practices must be followed. Computer systems involved in the development, manufacture, and sale of regulated product must meet certain requirements. Change control within quality management systems (QMS) and information technology (IT) systems is a formal process used to ensure that changes to a product or system are introduced in a controlled and coordinated manner. In the regulated industries, manufactures are required to use a change control procedure. In this presentation, I will discuss the connection between GxP/GMP and document control. I will describe details of document control procedures and the role of Quality Assurance in the documentation systems. I will review GMP requirements for information technology and how computer systems including documentation management systems must meet GxP/GMP requirements. I will also review change control procedure and how it should be used in GxP/GMP environment.

Biography:

Branislav Vlahovic is the Director of the National Science Foundation Computational Center of Research Excellence, NASA University Research Center for Aerospace Device and NSF Center Partnership for Research and Education in Materials at North Carolina Central University. In 2004, he was awarded by the Board of Governors of the University of North Carolina Oliver Max Gardner statewide award for his research and contribution to science. He has published more than 300 papers in peer reviewed journals on: Nanotechnology, Nanostructures, Tunneling and Charge Transfer between Nanostructures, Pulsed Laser Deposition, Nonlinear Optics, Detectors and Devices, Nano Photonics, Semiconductor Structures, Photovoltaic, and Genomics.

Abstract:

We consider that novel biochemical sensor based on the charge transfer between detector’s semiconductor nanostructures and analyte molecules that will be detected. It is an original concept that relies on the tunneling between an analyte molecule and the discrete energy levels of the detector’s nanostructures. The energy levels in nanostructures, which depend on quantum confinement and external effects, are tailored to mimic the energy levels of the analyte to be detected. Charge tunneling between the detector’s nanostructures and the analyte will occur only if the analyte has the energy levels matching the energy levels of the detector’s nanostructures. This completely new concept for biochemical sensor, which leverages the unique properties of nanostructured materials and design and optimization of detector’s nanostructure’s, provides label free detection and identification of a wide range of analyses, with single molecule sensitivities. Such unique detection method allows for continuous, instantaneous real time, high selectivity, high sensitivity, miniature in situ characterization device that could be implemented for various medical applications. The sensor may be a standalone unit, or it can serve as a part of an instrument, enhancing selectivity and sensitivity of that device. Discussed will be modeling of the optoelectronic properties of nanoscale materials and QDs for realistic QD detector ensembles, including the study of collective effects on energy level spectra and charge transfer processes between nanostructures; its application for detection in fluids; and the production of the sensor components and the final prototype device in our nanotechnology laboratory.